OpenAlex
PricingAboutJobs
Log inGet started
Work

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

HTML

Year: 2013
Type: article
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2012.45.6400
Authors: Franck Morschhauser, John Radford, Achiel Van Hoof, Barbara Botto, Ama Z.S. Rohatiner, Gilles Salles, Pierre Soubeyran, Herve Tilly, Angelika Bischof-Delaloye, Wim L.J. van Putten, Jelle W. Kylstra, Anton Hagenbeek
Institutions: St Bartholomew's Hospital, University of Manchester, Centre Hospitalier Universitaire de Lille, Hôpital Lyon Sud, Institut Bergonié, Centre Henri Becquerel
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: yttrium-90 ibritumomab tiuxetan, follicular lymphoma, consolidation therapy, first complete remission, progression-free survival, rituximab, CD20, autologous stem cell transplantation, time to next treatment, long-term follow-up, indolent lymphoma, second-line therapy, overall survival
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2080742973
FWCI: 20.48
Cites: 21
Cited by: 221
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms